NCT07205250 - Aspirin for Stroke Prevention After Endovascular Aortic Arch Repair: A Multicenter, Double-Blind, Randomized Controlled Trial | Biotech Hunter

Enrollment

538

Participants

Timeline

Start Date

October 8, 2025

Primary Completion Date

September 8, 2026

Study Completion Date

January 10, 2027

Conditions

Type B or Non-A Non-B Aortic Dissection;Thoracic Aortic Aneurysm

Interventions

DRUG

enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet)

Patients will be randomly divided into two groups: the aspirin group and the placebo group. Patients in the aspirin group will begin oral administration of enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet) on the first postoperative day. Patients in the placebo group will receive a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets. The oral medication course will last for six months.

OTHER

a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets

Patients will be randomly divided into two groups: the aspirin group and the placebo group. Patients in the aspirin group will begin oral administration of enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet) on the first postoperative day. Patients in the placebo group will receive a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets. The oral medication course will last for six months.